NCT Number: NCT02186665
Plaque Psoriasis Study in Pediatric Subjects
The purpose of this study is to compare the safety, efficacy and calcium metabolism of up to 8 weeks of treatment with calcitriol 3 mcg/g ointment versus its vehicle, when used twice daily, without occlusion, to treat children aged 2 to 12 years, with plaque psoriasis.
Looking for future studies?
Notify MeKey information
Conditions
Age range
2 year–12 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
Primary location
UCL Saint Luc, Brussels, Belgium
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Male or female 2 to 12 years of age
- Clinical diagnosis of stable mild to moderate plaque psoriasis
Exclusion criteria
- Other forms of psoriasis
- Hypercalcemia
- Past history of kidney stones
- Vitamin D deficiency
- Other concomitant dermatological disease
Treatment and study plan
placebo comparator
DrugPrimary outcomes
-
Success of Investigator's Global Assessment (IGA)
Time frame: Baseline to Week 8
The number of subjects with a minimum improvement of 2 grades from baseline in the IGA score and a severity rating of 0 (clear) of 1 (almost clear) at Week 8 (LOCF).
The IGA was evaluated at each visit on the following 0 to 4 point scale:
0 - Clear: No signs of psoriasis except for residual hypopigmentation / hyperpigmentation
- - Almost Clear: Just perceptible erythema, no induration, and no scaling
- - Mild: Mild erythema, no induration, and mild or no scaling
- - Moderate: Moderate erythema, mild induration, and mild or no scaling
- - Severe: Severe erythema, moderate to severe induration, and scaling of any degree
Sponsors and collaborators
Lead sponsor
Galderma R&D
Industry
Registry information
Official study title
A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis
Important dates
- Study start
- 2014
- Primary completion
- 2015
- Study completion
- 2016
- First posted
- Jul 10, 2014
- Registry last updated
- Feb 18, 2021
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis
NCT05772520
Plaque Psoriasis
Birmingham, Alabama, United States
View Trial DetailsEfficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study
NCT06648772
Plaque Psoriasis
Shenyang, Liaoning, China
View Trial DetailsStudy of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis
NCT05272150
Plaque Psoriasis, Scalp Psoriasis
Birmingham, Alabama, United States
View Trial DetailsGuselkumab Immunogenetics
NCT04645355
Guttate Psoriasis, Plaque Psoriasis
San Francisco, California, United States
View Trial Details